The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Certain batches of Solgar ABC Dophilus powder may pose a serious risk to your health, or the health of your child, and should not be taken.
The Therapeutic Goods Administration (TGA) has received advice from the United States Food and Drug Administration (USFDA) that testing of lot numbers 074024-01R1, 074024-01, 074024-02 Expiration Date 7/31/15 conducted by the Center for Disease Control of a product labelled Solgar ABC Dophilus powder found that those batches contain the presence of Rhizopus oryzae in 1.75 oz (50 g) containers. Consumers are advised:
- Rhizopus oryzae, can cause Mucormycosis, a rare infection that may cause health problems, particularly in pre-mature infants/infants and children; and
- a recall of Solgar ABC Dophilus powder - external site is currently being undertaken in the United States of America.
The supply of Solgar ABC Dophilus powder in Australia is illegal.
Solgar ABC Dophilus powder has not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation.
TGA investigations have shown that people in Australia may have bought the product online.
Information for consumers
- Stop taking or administering any affected batches of Solgar ABC Dophilus powder to your child and take any remaining product to your local pharmacy for safe disposal - external site.
- If you have any concerns arising from your use of this product, consult your health care practitioner.
Action the TGA is taking
The TGA is working with Australian Customs and Border Protection Service (ACBPS) to help stop future shipments of affected batches of Solgar ABC Dophilus powder from entering Australia.
If these batches are found at the border by ACBPS they may be seized and destroyed.
The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:
- may contain undisclosed and potentially harmful ingredients
- may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.
Report counterfeit medicines and medical devices
If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:
| Phone: | 1800 020 653 |
|---|---|
| Online: | Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products |
| Email: | info@tga.gov.au |